Trial Profile
A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Besifloxacin (Primary) ; Moxifloxacin (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- 07 Dec 2020 Status changed from recruiting to completed.
- 12 Jul 2011 Actual initiation date (May 2011) added as reported by ClinicalTrials.gov.
- 12 Jul 2011 Planned End Date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.